---
document_datetime: 2025-07-11 14:30:17
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sugammadex-fresenius-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sugammadex-fresenius-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3739675
conversion_datetime: 2025-12-30 21:11:13.705353
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sugammadex Fresenius Kabi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 02/06/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000256945   | variations.   |
|---------------------|---------------|

<div style=\"page-break-after: always\"></div>

| Minor change in the manufacturing process of the active substance - Accepted  B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted  B.I.d.1 Change in the re-test period/storage  period or storage conditions of the active  substance where no Ph. Eur. Certificate of  Suitability covering the retest period is part  of the approved dossier - B.I.d.1.c Change  to an approved stability protocol - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.a Minor changes to an  approved test procedure - Accepted  B.I.b.2 Change in test procedure for active  substance or starting  material/reagent/intermediate used in the  manufacturing process of the active  substance - B.I.b.2.z Other changes -  Accepted  B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.a Tightening of in-   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| process limits - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a test period/storage period supported by time data - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| re-                                                                                                                                                                           |
| real                                                                                                                                                                          |
| B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active                                                                                     |
| substance - B.I.a.4.z Other variation -                                                                                                                                       |
| Accepted                                                                                                                                                                      |
| B.I.b.1 Change in the specification                                                                                                                                           |
| parameters and/or limits of an active                                                                                                                                         |
| substance, starting material / intermediate /                                                                                                                                 |
| reagent used in the manufacturing process                                                                                                                                     |
| of the active substance - B.I.b.1.c Addition                                                                                                                                  |
| of a new specification parameter to the                                                                                                                                       |
| specification with its corresponding test                                                                                                                                     |
| method - Accepted                                                                                                                                                             |
| B.I.a.1 Change in the manufacturer of a                                                                                                                                       |
| starting material/reagent/intermediate used                                                                                                                                   |
| in the manufacturing process of the active                                                                                                                                    |
| substance or change in the manufacturer                                                                                                                                       |
| (including where relevant quality control                                                                                                                                     |
| testing sites) of the active substance, where                                                                                                                                 |
| no Ph. Eur. Certificate of Suitability is part of                                                                                                                             |
| the approved dossier - B.I.a.1.f Changes to                                                                                                                                   |
| active substance-replacement or addition of                                                                                                                                   |
| a site where batch control/testing takes                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                       | place - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                        |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000265804 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC have been updated following the same changes being adopted for the parent product. The Package Leaflet has been revised accordingly. C.I.11.z - The Risk Management Plan (RMP) has been updated to reflect the same changes | 23/05/2025 | 09/07/2025 | SmPC and PL |                                                                                                                                                                                        |
| Variation type IB / EMA/VR/0000253128 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (IB) - To update section 4.8 of the SmPC to add information on hypersensitivity                                                                                                                                                                                                          | 25/03/2025 | 09/07/2025 | SmPC        | To update section 4.8 of the SmPC to add information on hypersensitivity reactions for sugammadex-rocuronium complex, following approval of the same changes in the reference product. |

<div style=\"page-break-after: always\"></div>

| reactions for sugammadex-rocuronium complex, following approval of the same changes in the reference product. Furthermore, the Marketing Authorisation Holder has taken the opportunity to implement editorial changes in the CZ and PT local translations to align with the reference product.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|